Atracurium Besylate (64228-81-5)

  • For any enquiries about this API or any of Tofigh Daru’s other products, please contact:
  • Contact Us >>

Product Detail

Mechanism:

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. It binds to the nicotinic acetycholine (cholinergic) receptors in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated – causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrane remains depolarized and unresponsive to any other impulse, causing muscle paralysis. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Packaging: Polyethylene nylon plastic bag

Storage conditions: Preserve in tight, light resistant containers, in a cold palce.

CAS Number:  64228-81-5

Formula:  C65H82N2O18S2

Molecular Weight: 1243.48 g/mol

Method of Analysis:  USP Monograph

Application:

Atracurium Besylate is a synthetic dibenzensulfonate derivative muscle relaxant. Atracurium besylate is a complex molecule containing four sites at which different stereochemical configurations can occur. It is used in addition to other medications to provide skeletal muscle relaxation during surgery or mechanical ventilation. It acts as a non-depolarizing neuromuscular blocking agent, with short to intermediary duration of action and no significant cardiovascular effects. Not dependent on kidney function for elimination, it provides clinical advantages over other non-depolarizing, neuromuscular blocking agents.